Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

Baiyan Wang, MD PhD, Jie Liu, MD, Wan-Hong Zhao, MD PhD, Yin-Xia Chen, MD, Xing-Mei Cao, MD, Yun Yang, MD, Yi-Lin Zhang, MD, Fang-Xia Wang, MD PhD, Peng-Yu Zhang, MD PhD, Bo Lei, MD, Liu-Fang Gu, MD PhD, Jian-Li Wang, MD PhD, Frank Xiao-Hu Fan, MD PhD, Wang-Gang Zhang, MD PhD, Ai-Li He, MD PhD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-140243

Published: 2020

Journal Articles

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2019) 134 (Supplement_1): 579.

https://doi.org/10.1182/blood-2019-124953

Published: 2019

Journal Articles

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

Baiyan Wang, MD PhD, Jie Liu, MD, Yin-Xia Chen, MD, Xing-Mei Cao, MD, Wan-Hong Zhao, MD PhD, Jian-Li Wang, MD PhD, Xiao-Rong Ma, MD PhD, Yun Yang, MD, Peng-Yu Zhang, MD PhD, Fang-Xia Wang, MD PhD, Liu-Fang Gu, MD PhD, Bo Lei, MD, Jin Wang, MD PhD, Ju Bai, PhD, Yi-Lin Zhang, MD, Yan Xu, Ai-Li He, MD PhD, Wang-Gang Zhang, MD PhD

Blood (2018) 132 (Supplement 1): 5393.

https://doi.org/10.1182/blood-2018-99-116600

Published: 2018

Journal Articles

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2018) 132 (Supplement 1): 955.

https://doi.org/10.1182/blood-2018-99-110548

Published: 2018

Journal Articles

HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression

Xing-gang Wu, Yang Wang, Qian Wu, Wai-Hang Cheng, Wenjing Liu, Yueshui Zhao, Claire Mayeur, Paul J. Schmidt, Paul B. Yu, Fudi Wang, Yin Xia

Blood (2014) 124 (8): 1335–1343.

https://doi.org/10.1182/blood-2014-01-552281

Published: 2014

Includes: Supplemental data

Journal Articles

Method for Measuring Macrophage Iron Efflux in Vitro and in Vivo Using Magnetic Resonance Imaging

Bill Andriopoulos, Alexander R Guimaraes, Gregory R Wojtkiewicz, Sandra Chen, Yin Xia, Jodie L Babitt, Elena Corradini, Ralph Weissleder, Herbert Y Lin

Blood (2008) 112 (11): 4636.

https://doi.org/10.1182/blood.V112.11.4636.4636

Published: 2008

Journal Articles

Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin

Yin Xia, Jodie L. Babitt, Yisrael Sidis, Raymond T. Chung, Herbert Y. Lin

Blood (2008) 111 (10): 5195–5204.

https://doi.org/10.1182/blood-2007-09-111567

Published: 2008

Includes: Supplemental data

Journal Articles

Hemojuvelin Acts as a Bone Morphogenetic Protein Co-Receptor To Regulate Hepcidin Expression.

Franklin W. Huang, BS, Jodie L. Babitt, MD, Diedra M. Wrighting, MS, Tarek A. Samad, PhD, Yin Xia, PhD, Yisrael Sidis, PhD, Jason A. Campagna, Raymond T. Chung, MD, Alan L. Schneyer, PhD, Clifford J. Woolf, PhD, Nancy C. Andrews, MD, PhD, Herbert Y. Lin, MD, PhD

Blood (2005) 106 (11): 511.

https://doi.org/10.1182/blood.V106.11.511.511

Published: 2005

NARROW

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression

Method for Measuring Macrophage Iron Efflux in Vitro and in Vivo Using Magnetic Resonance Imaging

Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin

Hemojuvelin Acts as a Bone Morphogenetic Protein Co-Receptor To Regulate Hepcidin Expression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only